Zevalin combination shows positive results for non-Hodgkin's lymphoma

01/17/2008 | RTT News

Zevalin, an investigational radioimmunotherapy, combined with autologous stem cell transplantation and high-dose chemotherapy, had a 70% progression-free survival rate at two years in a Phase 2 study of non-Hodgkin's lymphoma patients who were ineligible for total-body irradiation, Cell Therapeutics announced. The study results will appear in the Journal of Clinical Oncology.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ